• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Fortress Biotech Inc.

    5/15/26 6:01:13 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBIO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Fortress Biotech, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    34960Q307

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    34960Q307


    1Names of Reporting Persons

    Highbridge Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,734,654.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,734,654.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,734,654.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IA, OO

    Comment for Type of Reporting Person:  Reflects shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Fortress Biotech, Inc.
    (b)Address of issuer's principal executive offices:

    1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the common stock, par value $0.0001 per share ("Common Stock") of Fortress Biotech, Inc., a Delaware corporation (the "Issuer"), issuable upon exercise of warrants directly held by the Highbridge Funds; The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of the Reporting Person is 390 Madison Avenue, 28th Floor, New York, NY 10017.
    (c)Citizenship:

    Highbridge is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    34960Q307
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 32,202,564 shares of Common Stock outstanding as of March 25, 2026, as reported in the Issuer's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 31, 2026, and assumes the exercise of the warrants held by the Highbridge Funds.
    (b)Percent of class:

    7.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the outstanding Common Stock.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Highbridge Capital Management, LLC
     
    Signature:/s/ Kirk Rule
    Name/Title:Kirk Rule, Executive Director
    Date:05/15/2026
    Get the next $FBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBIO

    DatePrice TargetRatingAnalyst
    3/15/2024$10.00Buy
    ROTH MKM
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $FBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference

    SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET. To register for the conference, visit the A.G.P. Registration Link. About Journey Medical Corpora

    5/19/26 4:45:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference

    MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 12:20pm ET. To register for the conference, visit the A.G.P. Registration Link. About Fortress BiotechFortress Biotech, Inc. ("Fortress")

    5/18/26 8:30:00 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress' consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted) MIAMI, May 14, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today anno

    5/14/26 4:10:00 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jin David

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    4/1/26 4:05:13 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rosenwald Lindsay A Md

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    3/20/26 4:05:13 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Weiss Michael S

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    3/20/26 4:05:10 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fortress Biotech Inc.

    SCHEDULE 13G/A - Fortress Biotech, Inc. (0001429260) (Subject)

    5/15/26 6:01:13 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Fortress Biotech Inc.

    10-Q - Fortress Biotech, Inc. (0001429260) (Filer)

    5/14/26 4:31:18 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Fortress Biotech, Inc. (0001429260) (Filer)

    5/14/26 4:23:01 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    9/25/24 4:45:04 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/15/24 4:05:14 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/12/24 8:42:21 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM resumed coverage on Fortress Biotech with a new price target

    ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

    3/15/24 7:18:10 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Fortress Biotech with a new price target

    Ladenburg Thalmann initiated coverage of Fortress Biotech with a rating of Buy and set a new price target of $6.00

    8/4/22 7:17:35 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on Fortress Biotech with a new price target

    Roth Capital reiterated coverage of Fortress Biotech with a rating of Buy and set a new price target of $5.00 from $4.50 previously

    4/20/21 8:28:52 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortress Biotech Inc.

    SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

    10/25/24 10:15:19 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

    SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

    9/25/24 4:45:18 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Fortress Biotech Inc. (Amendment)

    SC 13G/A - Fortress Biotech, Inc. (0001429260) (Subject)

    2/14/24 4:51:41 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Financials

    Live finance-specific insights

    View All

    Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress' consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted) MIAMI, May 14, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today anno

    5/14/26 4:10:00 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

    Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million  Emrosi® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corp

    5/13/26 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

    SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 13, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the

    5/6/26 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

    SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

    7/11/24 4:05:39 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care